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TLR4 and MD-2 form a heterodimer that recog-
nizes LPS (lipopolysaccharide) from Gram-neg-
ative bacteria. Eritoran is an analog of LPS that
antagonizes its activity by binding to the TLR4-
MD-2 complex. We determined the structure of
the full-length ectodomain of the mouse TLR4
and MD-2 complex. We also produced a series
of hybrids of human TLR4 and hagfish VLR and
determined their structures with and without
bound MD-2 and Eritoran. TLR4 is an atypical
member of the LRR family and is composed of
N-terminal, central, and C-terminal domains.
The b sheet of the central domain shows unusu-
ally small radii and large twist angles. MD-2
binds to the concave surface of the N-terminal
and central domains. The interaction with
Eritoran is mediated by a hydrophobic internal
pocket in MD-2. Based on structural analysis
and mutagenesis experiments on MD-2 and
TLR4, we propose a model of TLR4-MD-2
dimerization induced by LPS.
INTRODUCTION
Innate immunity provides immediate and efficient defense
against microbial infection. It promotes inflammatory re-
sponses and also plays a role in the induction of the adap-
tive immune system that recognizes specific antigens.
Toll-like receptors (TLRs), a family of type I transmem-
brane glycoproteins, are central to vertebrate innate im-
mune responses (Gay and Gangloff, 2007; Medzhitov
et al., 1997). They recognize broad but highly conserved906 Cell 130, 906–917, September 7, 2007 ª2007 Elsevier Inc.structural patterns on bacteria, fungi, and viruses, which
are generally absent from host molecules and are called
pattern recognition receptors. To date, 13 mammalian
members of the TLR family have been identified, and six
subfamilies have been defined based on function and se-
quence characteristics (Matsushima et al., 2007; Roach
et al., 2005). The extracellular segments of TLRs consist
of leucine-rich repeats (LRR) with horseshoe-like shapes
(Gay and Gangloff, 2007). Binding of ligands to the extra-
cellular domains of TLRs causes a rearrangement of the
receptor complex and triggers the recruitment of specific
adaptor proteins to the intracellular domain, thus initiating
a signaling cascade.
TLR4 is composed of a 608 residue extracellular do-
main, a single transmembrane domain, and a 187 residue
intracellular domain (Medzhitov et al., 1997). MD-2, which
lacks transmembrane and intracellular regions, associ-
ates with the extracellular domain of TLR4 and is believed
to be the component of the TLR4-MD-2 complex that in-
teracts with LPS (lipopolysaccharide) (Shimazu et al.,
1999; Viriyakosol et al., 2001). LPS is an outer membrane
glycolipid of Gram-negative bacteria and a well-known in-
ducer of the innate immune response (Raetz andWhitfield,
2002). It is composed of a hydrophobic lipid A component
and the hydrophilic polysaccharides of the core and
O-antigen. The lipid A portion, which is composed of
phosphorylated di-glucosamine and multiple acyl chains,
corresponds to the conserved molecular pattern of LPS
and is the main inducer of biological responses to LPS.
LPS is extracted from the bacterial membrane and trans-
ferred to TLR4 by two accessory proteins, LPS-binding
protein (LBP) and CD14 (Miyake, 2006).
TLR4 and MD-2 are essential for LPS recognition. The
C3H/HeJ strain of mice, which tolerates lethal doses of
LPS and has altered inflammatory responses, was found
to have a missense mutation in the conserved region of
Figure 1. Overall Structure of the Mouse
TLR4-MD-2 Complex
(A–C) Three views of the mouse TLR4-MD-2
complex are shown in the diagrams. The
N-terminal, central, and C-terminal domains
of TLR4 are colored in blue, cyan, and green,
respectively. The beta strands of MD-2 are
shown in pink and red, and the LRR modules
of TLR4 are numbered.
(D) Closeup view of mouse MD-2. Disulfide
bridges are shown in yellow and cysteines
are labeled. Cys133 is not involved in the di-
sulfide bridge formation. The orientation of
this view is the same as for (C).the TLR4 intracellular domain (Poltorak et al., 1998; Qure-
shi et al., 1999). Similar tolerance was observed in the
C57BL/10ScCr mutant, which has a deletion of the entire
tlr4 locus, and in TLR4-deficient mice (Hoshino et al.,
1999; Poltorak et al., 1998; Qureshi et al., 1999). However,
transfection of TLR4 alone is not enough for LPS recogni-
tion, and physical association of TLR4 with MD-2 on the
cell surface is a prerequisite for ligand-induced activation
(Nagai et al., 2002; Schromm et al., 2001; Shimazu et al.,
1999). LPS has similar affinity for MD-2 as for the TLR4-
MD-2 complex, demonstrating that MD-2 is the LPS-
binding component (Viriyakosol et al., 2001). Only the
monomeric form of soluble recombinant MD-2 was found
to bind LPS, producing a stable MD-2-LPS complex, and
this complex was sufficient for inducing TLR4-dependent
activation (Gioannini et al., 2004; Re and Strominger,
2002).
Engagement of LPS on the host cell activates a strong
immune response that protects the human body against
further infection. However, it can also lead to a fatal septic
syndrome if the inflammatory response is amplified and
uncontrolled. Eritoran (or E5564) is a synthetic molecule
derived from the lipid A structure of the nonpathogenic
LPS of Rhodobacter sphaeroides (Mullarkey et al., 2003;
Rossignol and Lynn, 2005). It is a strong antagonist
of TLR4-MD-2 and is currently in a phase III clinical trial
for severe sepsis. Although the first crystal structures of
TLR3 was recently reported (Bell et al., 2005; ChoeCet al., 2005), the structural basis of ligand binding and ac-
tivation of TLR family proteins still remain to be clarified.
To address these questions, we undertook structural
studies of TLR4-MD-2 and its complex with Eritoran.
RESULTS
Structure of Mouse TLR4
To determine the structure of the mouse TLR4-MD-2
complex, the full-length ectodomains of mouse TLR4
and MD-2 were expressed in cultured insect cells using
recombinant baculoviruses. The mouse TLR4 and MD-2
proteins form a stable 1:1 complex and are not separated
during purification. In the crystal structure, one molecule
of MD-2 binds to each TLR4, confirming previous reports
that only monomeric MD-2 interacts with TLR4 and medi-
ates LPS signaling (Figure 1) (Gioannini et al., 2004, 2005;
Re and Strominger, 2002).
The crystal structure shows that TLR4 is an unusual
member of the ‘‘typical’’ subfamily of the LRR superfamily.
Typical subfamily LRR proteins have characteristic horse-
shoe-like structures whose concave surface is formed by
parallel b strands and whose convex surface is formed by
loops and 310 helices (Kajava, 1998; Kobe and Kajava,
2001). The parallel b sheet of the typical subfamily has uni-
form twist angles and radii throughout the entire protein.
Unlike other typical family members including TLR3, anal-
ysis of the b sheet conformation of TLR4 demonstratesell 130, 906–917, September 7, 2007 ª2007 Elsevier Inc. 907
Figure 2. SequenceAlignments and Sec-
ondary Structure Assignments of TLR4
and MD-2
(A) Structure-based alignment of human and
mouse TLR4 sequences. b strands and a heli-
ces of the TLR4 and MD-2 are shown above
the sequence alignment as arrows and cylin-
ders, respectively. Residues involved in the
asparagine ladder and phenylalanine spine
are colored green and cyan, respectively. Res-
idues important for the MD-2 interaction are in
bold and underlined.
(B) Sequence alignment and secondary struc-
ture assignment of human and mouse MD-2. b
strands in the two b sheets are colored pink
and red, respectively. Residues involved in
TLR4 binding are written in bold and under-
lined.that it can be divided into N-, central, and C-terminal do-
mains and undergoes sharp structural transitions at the
domain boundaries (Figures 1A–1C and S1 and Table S1).
The N-terminal domain starts from amino acid residue
26 and ends at residue 201 and contains the LRRNTmod-
ule and LRRmodules 1 to 6 (Figure 2). The LRRNTmodule
has no sequence homology with the LRR modules and
protects the otherwise exposed hydrophobic cores of
the LRR modules. The sequences of the six LRR modules
in the N-terminal domain agree well with the conserved
pattern of LRR modules of the typical subfamily. The ra-
dius and twist angle of the N-terminal domain also agree
well with those of typical LRR subfamily members (Table
S1). The C-terminal domain of TLR4 contains the LRRCT
module and LRR modules 13 to 22. The radius of the
b sheet of the C-terminal domain is 28% larger than that
of the N-terminal domain. Like LRRNT, the LRRCTmodule
contains two disulfide bonds and covers the hydrophobic
core of the LRR modules at the C terminus.
The central domain is composed of LRR modules 7 to
12 and has a 35% smaller radius and three times greater
twist angles than those of TLR3 (Table S1). It includes908 Cell 130, 906–917, September 7, 2007 ª2007 Elsevier Inc.the ‘‘hypervariable’’ region that is essential for recognition
of an LPS variant from P. aeruginosa (Hajjar et al., 2002).
The conformational variation of the central domain ap-
pears to originate from three changes in its sequence con-
servation pattern (Figure 2). (1) The standard LRR module
contains two variable amino acids between the first and
second conserved leucines. However, the LRR modules
of the central domain have only one variable residue. (2)
Signature residues important in the structure of the ‘‘typi-
cal’’ subfamily LRR proteins are missing from the central
domain. In the typical subfamily, the conserved aspara-
gines form a continuous hydrogen-bonding ladder and
the phenylalanines form a hydrophobic spine (He et al.,
2003; Kim et al., 2007). In TLR4, the asparagine ladder is
absent from LRR modules 9 12 and the phenylalanine
spine is broken at the border between the central and
the C-terminal domain. (3) The lengths of the LRRmodules
of the central domain vary considerably, ranging from 20
to 30 amino acid residues. The length of the LRR module
is strongly correlated with the overall shape of the horse-
shoe-like structure. The LRR superfamily consists of six
subfamilies, within which the lengths of the LRR modules
are conserved (Kajava, 1998; Kobe and Kajava, 2001).
Subfamilies with shorter LRR modules have loops in their
convex regions, and those with longer ones have a-helical
structures. Since an a helix requires more space than
loops, the horseshoe-like structureswith longer LRRmod-
ules have smaller radii. Thus the large variation in the
length of the LRR modules appears to affect the radius
and shape of the horseshoe-like structure of the central
domain.
Structure of Mouse MD-2
MD-2 adopts a b cup fold with two antiparallel b sheets
that contain three and six b strands, respectively (Fig-
ure 1D). The b cup fold is different from the immuno-
globulin fold although both of them contain sandwiched
antiparallel b sheets (Derewenda et al., 2002; Friedland
et al., 2003; Wright et al., 2003). In the b cup fold, the
two b sheets become separated on one side of the protein
and the hydrophobic internal core is open for ligand bind-
ing. Furthermore, the conserved disulfide bridge that
connects the two b sheets in the immunoglobulin fold is
absent from the b cup so that the two sheets can be sep-
arated, further permitting the formation of a large internal
pocket. The MD-2 pocket is narrow and deep with a total
surface area of 1000 A˚2. The overall shape and chemical
behavior of the pocket appear to be suitable for binding
large flat molecules such as LPS that contain multiple
hydrophobic acyl chains and negatively charged phos-
phate groups. The generous internal surface of the pocket
is completely lined with hydrophobic residues, and the
opening region of the pocket contains positively charged
residues that facilitate the binding of LPS.
Unlike the majority of globular proteins, MD-2 does not
have a sizable hydrophobic core because almost all of its
hydrophobic residues are involved in forming the internal
pocket. Therefore other structural elements appear to
have amore important effect on the stability of the protein.
The disulfide bridge connecting Cys25 and Cys51, to-
gether with hydrogen bonds between Tyr34, Tyr36, and
the backbone atoms of the bC strand, close the bottom
of the pocket and stabilize the cup-like structure (Fig-
ure 1D). The remaining two disulfide bridges buttress
structures of the loops connecting the b strands.
Interaction between TLR4 and MD-2
The surface of TLR4 that interacts with MD-2 has a long
and narrow shape with dimensions 40 3 20 A˚ (Figure 3A).
It can be divided into two chemically and evolutionarily
distinct areas, the A and B patches. The A patch is nega-
tively charged and evolutionarily conserved, whereas the
B patch is positively charged and located in a less con-
served area, although the residues directly interacting
with MD-2 are strictly conserved (Figures 3B and 3C).
The A and B patches of TLR4 are composed of the resi-
dues in the concave surface derived from the ‘‘LxLxxN’’
part of the LRR modules in the N-terminal domain and of
the central domain, respectively (Figure 2). The interaction
between TLR4 andMD-2 is mediated by an extensive net-work of charge-enhanced hydrogen bonds (Figure 3A).
The negatively charged residues in the A patch interact
with the positively charged Arg68 and Lys109 residues
in MD-2. The positively charged B patch interacts with
negatively charged residues in the loop between the bF
strand and the a helix ofMD-2. The parts of MD-2 interact-
ing with the A andB patches of TLR4 are named the A0 and
B0 patches, respectively, in Figure 3. The large interaction
area and the complementary charge distribution over the
Figure 3. Interactions between TLR4 and MD-2
(A) Closeup view of the interaction region between TLR4 and MD-2.
Residues involved in the interaction are labeled. The disulfide bridges
are shown in yellow. Hydrogen bonds are drawn with broken lines. Hy-
drogen bond distances are 3.1, 2.5, 3.1, 2.9, and 2.9 A˚ for the R68-D41,
K109-D83, E111 backbone-E134, D100-R233, and D99-R288 pairs,
respectively.
(B) Electrostatic potentials of TLR4 and MD-2. The surface potential
was calculated and displayed using the CCP4 mg program (Potterton
et al., 2004). The interaction patches of TLR4 andMD-2 are circled and
labeled. The orientation of the view of TLR4 is similar to that of
Figure 1B. In order to show the binding surface, MD-2 is rotated 180
degrees along the vertical axis.
(C) Sequence conservation of TLR4 and MD-2. Conservation scores
were calculated by the Bayesian method using the Consurf server
(Landau et al., 2005). Residues directly involved in the TLR4-MD-2 in-
teraction are strictly conserved except for Asp41 and Lys263 of TLR4,
which are conservatively changed to glutamates and arginines, re-
spectively, in some species.Cell 130, 906–917, September 7, 2007 ª2007 Elsevier Inc. 909
Figure 4. Assembly of the Full-Length
Ectodomain of Human TLR4
Structures of the three human TLR4-VLRB.61
hybrids. TLR4 fragments are colored blue and
VLRB.61 fragments gray. The full-length ecto-
domain of human TLR4 was assembled after
superimposition of the overlapping regions of
the TV8 and VT3 hybrids. The disulfide bridges
are represented in orange.interaction surface are consistent with the nanomolar
binding affinity of TLR4-MD-2 (Hyakushima et al., 2004).
Previous reports support our structural observations.
Nishtani et al. have shown thatmutations of TLR4 residues
Cys29 and Cys40, and a synthetic peptide including the
residues fromGlu24 to Lys47 of TLR4, block TLR4 binding
to MD-2 (Nishitani et al., 2005, 2006). This region is not
only important for the structural integrity of the LRRNT
module but also contains Asp41, a crucial component of
the A patch of TLR4. Mutations of MD-2 residues Cys95,
Cys105, Asp99, Asp100, and Asp101 in the B0 patch
have also been shown to disrupt TLR4 binding (Re and
Strominger, 2003).
Designing Hybrids of Human TLR4
and Hagfish VLR
To facilitate soluble expression and crystallization of the
TLR4-MD-2 complex with bound ligands, we have devel-
oped a novel technique that we term the ‘‘Hybrid LRR
Technique’’ in this article. Difficulties in producing target
proteins in soluble form and in crystallizing them are the
two most common obstacles to successful crystallo-
graphic studies. These problems can sometimes be by-
passed by removing nonessential domains because
many proteins have multiple domains linked by flexible
loops, and biological function is often dependent on do-
mains much smaller than the full-length protein. All natural
LRR proteins including TLR4 have two specialized mod-
ules, LRRNT and LRRCT, that cover the otherwise ex-
posed central hydrophobic core of the LRR modules (Ka-
java, 1998; Kobe and Kajava, 2001). Truncation of the LRR
modules in a target protein will also remove these structur-
ally indispensable LRRNT or LRRCT modules. To avoid
this problem we fuse truncated fragments of TLR4 with
the LRRNT or LRRCT modules from other LRRs. The
VLR proteins of hagfish were chosen as fusion partners
because all VLR proteins have canonical LRR structures
with sequence diversity in their variable regions maxi-
mized (Kim et al., 2007). Therefore good fusion partners910 Cell 130, 906–917, September 7, 2007 ª2007 Elsevier Inc.can be selected from a large pool of diverse VLR proteins.
By varying fusion partners and the site of fusion of pairs of
proteins, this technique can generate a practically unlim-
ited number of hybrid LRR proteins without loss of struc-
tural integrity.
After many unsuccessful attempts we realized that the
‘‘LxxLxLxxN’’ regions of the LRR modules would be the
best fusion sites because they are highly conserved and
their structures are practically invariant (Kajava, 1998;
Kobe and Kajava, 2001) so that one can predict the struc-
ture of the resulting hybrid proteins with great confidence.
Relative positions of the conserved residues were strictly
preserved at the fusion sites (Table S2). This fusion strat-
egy was surprisingly successful, such that of 15 fusion
proteins designed, 7 yielded soluble hybrids (Table S2).
Some of the hybrids were tested and found to bind MD-
2 and to yield crystals. Furthermore, like the full-length
ectodomain of TLR4, the longest TV8 hybrid could be
multimerized by LPS (details in the section ‘‘Dimerization
of the TLR4 and MD-2 complex’’). From the analysis of
the hybrid structures, we were convinced that the Hybrid
LRR Technique did not cause substantial structural
changes (See below ‘‘Structural rigidity of the LRR mod-
ules in the TLR4-VLR hybrids’’ section) and the complete
structure of the ectodomain of human TLR4 was gener-
ated by aligning the overlapping regions of the TV8 and
VT3 structures (Figure 4).
Structure of the TLR4-MD-2-Eritoran Complex
Among the hybrids, MD-2-bound TV3 was successfully
crystallized with Eritoran and their complex structure
was solved (Figure 5). Eritoran binds to the hydrophobic
pocket in human MD-2, and there is no direct interaction
between Eritoran and TLR4. The structure formed by the
four acyl chains of Eritoran complements the shape of
the hydrophobic pocket and snuggly occupies almost
90% of the solvent-accessible volume of the pocket, leav-
ing only a narrow groove near its opening (Figures 5B and
5C). Although the R2 and R3 acyl chains adopt a fully
Figure 5. Structure of the TLR4-MD-2-
Eritoran Complex
(A) Overall structure of the TV3-hMD-2-Eritoran
complex. The TLR4 part of TV3 is colored blue
and the VLR part gray.
(B) Closeup view of the human MD-2 and
Eritoran complex. The bound TV3 hybrid is
omitted for clarity. The carbon, oxygen, and
phosphorous atoms of Eritoran are green,
red, and orange, respectively. MD-2 residues
interacting with the hydrophobic acyl chains
of Eritoran are colored magenta and labeled.
(C) Shape of the Eritoran-binding pocket. The
surface of MD-2 is drawn in purple mesh. The
four acyl chains of Eritoran are labeled.
(D) Chemical structure of Eritoran. MD-2 resi-
dues interacting with Eritoran are labeled. The
b strands are shown schematically as broken
arrows.
(E) Surface representation of MD-2. Positively
and negatively charged surfaces are colored
blue and red, respectively. Lysines and argi-
nines interacting ionically with Eritoran are
labeled. The bound TV3 hybrid is omitted for
clarity.extended conformation, the R20 and R30 acyl chains are
bent in the middle (Figure 5C). The double bond of the
R20 acyl chain has a cis conformation, and the chain
makes a 180 degree turn at the cis double bond to occupy
the empty space in the pocket (Figure 5D).
The di-glucosamine backbone of Eritoran conserved in
all LPS molecules is fully exposed to solvent. Although
the di-glucosamine sugars do not interact directly with
MD-2, the two phosphate groups attached to the back-
bone form ionic bonds with several positively charged res-
idues located at the opening of the pocket (Figures 5D and
5E). This is consistent with biochemical studies showing
that thedi-glucosaminegroupsaredispensable for binding
of synthetic ligandsderived fromLPS toMD-2,whereas the
phosphate groups are essential (Brandenburg et al., 2004).
The TV3 hybrid does not contain the B patch but still
forms a stable complex with MD-2, suggesting that the
A patch of TLR4 plays the major role in MD-2 interaction.
This is consistent with the evolutionary analysis of TLR4
where the A patch shows higher conservation than the B
patch (Figure 3C). All the residues involved in the A-A0
patch interaction are present in the TV3-MD-2 complex,
and deletion of the B patch induces no substantial struc-
tural changes in the interaction of the A and A0 patches.CStructural Comparison of TLR4 and MD-2
with Related Proteins
We compared the structures of mouse TLR4 in complex
with MD-2 and the human TLR4 without bound MD-2.
Mouse and human TLR4 have 62.4% sequence identity
and therefore are expected to have highly homologous
structures. Indeed, the N- and C-terminal domains of the
two TLR4 structures could be superimposed with average
Ca rms differences of 0.66 A˚ and 1.56 A˚, respectively
(Figure S2). The largest structural differences of the
C-terminal domain were located in the LRRCT module,
where the insertion of Glu563 in human TLR4 caused a
3.5 A˚ displacement of the LRRCT module.
The central domains differ substantially more in struc-
ture than the N- and C-terminal domains. MD-2-bound
mouse TLR4 has its LRR9 loop shifted by more than
12 A˚, which bends the entire horseshoe-like structure
by approximately 20 degrees. The observed structural
change is unlikely to be due to the sequence differences
between human and mouse TLR4 central domains. These
are 56% identical, and residues with clear structural roles
are strictly conserved. Instead, the structural change is
likely to be caused by MD-2 binding because the LRR9
loop of mouse TLR4 occupies the central region of the Bell 130, 906–917, September 7, 2007 ª2007 Elsevier Inc. 911
patch and interacts at many points with MD-2 (Figure 3A).
Future crystallographic experiments using MD-2-free
mouse TLR4 are required to confirm the origin of the struc-
tural changes in the central domain.
Mouse and human MD-2 share 64% sequence identity.
As expected, the two MD-2 structures show high struc-
tural homology with a Ca rms difference of 1.2 A˚ (Fig-
ure S3A). It should be noted that our mouse MD-2 is com-
plexed with the full-length ectodomain of mouse TLR4 but
without any bound ligands, whereas human MD-2 is com-
plexedwith the shorter TV3 hybrid and Eritoran. Except for
small shifts in the B0 patch and the loops between the bG-
bH and bA-bB strands, binding of Eritoran or deletion of
the B patch in TV3 did not induce significant structural
changes in MD-2. Lipid IVa is the precursor form of
lipid A. It has an antagonistic effect on human TLR4-
MD-2 but an agonistic effect on the mouse TLR4-MD-2
complex. Both MD-2 and TLR4 have been reported to
be important for the species-specific response to lipid
IVa (Lien et al., 2000; Muroi and Tanamoto, 2006; Poltorak
et al., 2000). The residues important for the species-
specific response are Thr57, Val61, and Glu122 of mouse
MD-2 (Muroi and Tanamoto, 2006). In our crystal struc-
ture, they show only minor structural changes between
human and mouse MD-2s, suggesting that subtle struc-
tural changes in MD-2 may have a significant impact on
activation of TLR4-MD-2 (Figure S3B).
MD-2 shares the b cup topology with the ML family of
lipid-binding proteins (Gruber et al., 2004; Inohara and Nu-
nez, 2002). A search of the structural neighborhood of
MD-2 in the Dali database yielded GM2 activator protein
and NPC2 at the top, with Z values of 7.5 and 6.3, respec-
tively (Figure S4). TheML family proteins have two antipar-
allel b sheets and conserved disulfide bridges (Derewenda
et al., 2002; Friedland et al., 2003; Wright et al., 2003).
However, the structural similarity betweenMD-2 and other
ML family proteins is restricted to the overall connectivity
of the b strands, and the MD-2 structure could not be
superimposed on any of the ML family proteins; MD-2
has more b strands and a larger ligand-binding pocket.
The shape of the ligand-binding pocket of MD-2 suggests
that it has evolved to accommodate large and structurally
diverse ligands.
Dimerization of the TLR4 and MD-2 Complex
It has been reported that binding of agonistic LPS induces
aggregation of TLR4 and initiates intracellular signaling
(Kobayashi et al., 2006; Prohinar et al., 2007). To further
characterize the structural properties of the TLR4 multi-
mer, we investigated the aggregation state of purified
TLR4-MD-2 after binding LPS, using gel filtration chroma-
tography, native gel electrophoresis, and crosslinking
experiments (Figures 6A–6C). Binding of Eritoran to the
full-length ectodomains of mouse and human TLR4-MD-
2 did not alter their elution volumes in gel filtration chroma-
tography and caused only small changes in migration
speed in native gel electrophoresis (Figures 6A and 6B).
In contrast, binding of LPS caused large changes in the912 Cell 130, 906–917, September 7, 2007 ª2007 Elsevier Inc.aggregation state of the TLR4-MD-2 complexes. LPS-
bound TLR4-MD-2 eluted earlier in gel filtration chroma-
tography and shifted upwards in native gel electrophore-
sis. The elution volume of the LPS-bound protein complex
in the gel filtration chromatography was consistent with
the predicted elution volume of a TLR4-MD-2 hetero-
tetramer (Figure 6A). Furthermore, the LPS-bound TLR4-
MD-2 formed a band consistent with the size of the
TLR4-MD-2 heterotetramer after crosslinking with glutar-
aldehyde and SDS gel electrophoresis (Figure 6C). The
central and/or C-terminal domains of TLR4 are required
for the receptor dimerization because the TV3 hybrid
that contains only the N-terminal domain and a part of
the central domain interacts normally with MD-2 but did
not form a heterotetramer after LPS binding (Figures 6A
and 6B). On the other hand, the TV8 hybrid composed of
the N-terminal, the central, and 75% of the C-terminal do-
main behaved similarly with the full-length ectodomain
TLR4 in LPS-induced multimerization. Collectively, these
experiments demonstrate that LPS, but not Eritoran,
causes dimerization of the TLR4-MD-2 complex, and
that dimerization requires the central and/or the C-termi-
nal domains of TLR4.
To locate the residues of MD-2 involved in dimerization
we performed site-directed mutagenesis experiments.
Kobayashi et al. have shown that mutations of Phe126
and Gly129 in mouse MD-2 prevent aggregation of the
TLR4-MD-2 complex (Kobayashi et al., 2006). These res-
idues are both opposite to the TLR-4-binding site of MD-2
(Figure 6D). To further characterize this Phe126 edge of
MD-2, we conducted additional mutagenesis experi-
ments. Phe126 and His155 mutants of MD-2 bound as
normal to TLR4 and LPS, but their complex with TLR4
was not dimerized by LPS (Figure 6E). Although the
Val82 and Met85 residues are located close to Phe126
and His155, altering them bymutation did not affect multi-
merization of the TLR4-MD-2 complex; this finding con-
firms that the Phe126 and His155 residues play specific
roles in receptor dimerization.
DISCUSSION
Model of LPS Bound to TLR4-MD-2
The mode of interaction of the TLR4-MD-2 complex with
Eritoran reported in this article is likely to resemble that
with LPS for the following reasons. (1) Because Eritoran
competes with LPS for binding to MD-2 (Visintin et al.,
2005), their binding sites must at least overlap. (2) Eritoran
is derived from the lipid A structure of Rhodobacter
sphaeroides LPS. The di-glucosamine backbone is con-
served and the lipid chains are very similar in chemical
structure (Rossignol and Lynn, 2005). (3) Recently Ohto
et al. reported a crystal structure of human MD-2 in com-
plex with lipid IVa (Ohto et al., 2007). In their and our MD-2
structures, lipid IVa and Eritoran bind to the same area in
MD-2 (Figure S5). The bound di-glucosamine backbone
and the lipid chains of lipid IVa show small but interesting
Figure 6. Dimerization of the TLR4-MD-2
Complex
(A) Gel filtration chromatography of the TLR4-
MD-2 complexes. Full-length and hybrid
TLR4 proteins in complex with MD-2 were in-
cubated with LPS Ra or Eritoran and analyzed
by Superdex 200 gel filtration chromatogra-
phy, calibrated with molecular weight stan-
dards. The apparent molecular weights of the
complexes calculated from the elution vol-
umes are shown, and the expected molecular
weights of the monomeric TLR4-MD-2 com-
plexes are given in parentheses.
(B) Native and SDS-PAGE analysis of the
TLR4-MD-2 complexes. The TLR4-MD-2 com-
plexes were incubated with Eritoran or E. coli
LPS Ra and analyzed. Dimerized complexes
migrate more slowly than the monomeric com-
plex and aremarkedwith *. The Eritoran-bound
protein complexes run slightly faster than the
unbound complexes due to the negative
charges on the ligand.
(C) Glutaraldehyde crosslinking of the TLR4-
MD-2 complex. The TLR4-MD-2 complex not
bound to LPS (left lanes) was crosslinked as
a monomeric TLR4-MD-2 complex with the
expected molecular weight of 85 kDa. The
LPS-bound TLR4-MD-2 complex was cross-
linked as a dimer with the expected molecular
weight of 170 kDa.
(D) Positions of the Phe126 and His155 resi-
dues. These residues are located on the oppo-
site side of TLR4. The full-length ectodomain of
TLR4 was modeled by superimposing the TV3
and mouse TLR4 structures and its surfaces
are shown in blue, cyan, and green.
(E) Dimerization of the mutant MD-2 s with
TLR4 and LPS Ra. TLR4 and mutant MD-2
complexes were incubated with E. coli LPS
Ra and analyzed by native gel electrophoresis.
The dimerized protein complexes run more
slowly than the monomeric protein complex
and are marked with *.structural changes compared to those of Eritoran. (4) All
ML family proteins are small and have only one ligand-
binding pocket. The Eritoran-binding pocket of MD-2 is lo-
cated in the same region where GM2 activator protein, Der
P2, and NPC2 have been proposed to interact with their
ligands (Derewenda et al., 2002; Friedland et al., 2003;
Wright et al., 2003). (5) Previousmutagenesis results dem-
onstrate that several residues involved in Eritoran binding
also play indispensable roles in LPS binding. Lys89,
Arg90, Lys91, Lys122, Lys125, Lys128, and Lys132, which
are reported to be essential for LPS binding and NFkB
activation, are located near the opening of the Eritoran-
binding pocket and interact ionically with the phosphate
groups in Eritoran (Figure 5E) (Gruber et al., 2004; Re
and Strominger, 2003; Visintin et al., 2003).
Although Eritoran has a clear structural resemblance to
LPS, they have opposite physiological effects: Eritoran is
an antagonist and LPS an agonist. Therefore, there must
be significant differences in their modes of interaction.CThe length and number of acyl chains in natural LPS
vary between bacterial species and appear to be strongly
correlated with agonist strength (Teghanemt et al., 2005).
E. coli and Salmonella LPSs usually have six acyl chains
and are strong agonists of TLR4. Since the four acyl chains
of Eritoran occupy almost all the available space in the
MD-2 pocket, significant structural changes of the pocket
appear to be inevitable when more, or longer, acyl chains
are accommodated. These structural changes in MD-2
induced by LPS binding may reveal an otherwise hidden
binding site required for aggregation and activation of
the TLR4-MD-2 complex.
Model of the LPS-Induced TLR4-MD-2
Dimerization
The mutagenesis data reported by us and by Kobayashi
et al. show that the Phe126 edge of MD-2 mediates the
aggregation of the TLR4-MD-2 complex (Kobayashiell 130, 906–917, September 7, 2007 ª2007 Elsevier Inc. 913
Figure 7. Model of the TLR4-MD-2 Dimer
(A) Three models of the TLR4-MD-2 dimer are
shown.MD-2 and TLR4 are colored inmagenta
and gray, respectively. The yellow bars repre-
sent the cell membrane.
(B) Three-dimensional representation of Model
3. Surfaces of TLR4 and MD-2 are gray and
magenta, respectively. The Phe126 and
His155 residues important for dimerization
are blue. The labels that belong to the second
TLR4-MD-2 complex are marked with
apostrophes.et al., 2006). We also found that receptor dimerization re-
quires the central and/or C-terminal domain of TLR4.
Three models of receptor dimerization are shown in
Figure 7A. In the first model, LPS binding induces a struc-
tural change in the Phe126 edge of MD-2, which then
makes direct contact with a second MD-2 molecule.
This model cannot explain why the central or C-terminal
domain of TLR4 is required for receptor dimerization. In
the second model, LPS binding to MD-2 induces a struc-
tural change in TLR4 and promotes direct dimerization of
TLR4 molecules. This model cannot explain why muta-
tions in the Phe126 edge of MD-2, which is located on
the opposite side of TLR4, block receptor dimerization.
The possibility of a long-range effect of the MD-2 muta-
tions by inducing conformational changes of TLR4 cannot
be excluded but is very unlikely considering the unusually
high structural rigidity of the LRR modules in TLR4 (see
next section). In the favored third model, LPS binding
induces a structural change in the Phe126 edge of MD-2
that promotes interaction between the edge and the
central or C-terminal domain of a second TLR4. A three-
dimensional view of model 3 demonstrates that the intra-
cellular TIR domains can form close contact (Figure 7B).
CD14 is indispensable for physiological response of
LPS by catalyzing binding of LPS to the TLR4-MD-2 com-
plex and by modulating signaling activity of LPS (Haziot
et al., 1995; Jiang et al., 2005; Miyake, 2006). Mutations
of CD14 that block LPS transfer to TLR4-MD-2 are clus-
tered in one face of CD14 near its LPS-binding pocket
(Kim et al., 2005). Future biochemical and structural
research is required to identify a CD14 interaction site in
TLR4-MD-2 and the mechanism of LPS transfer from
CD14 to TLR4-MD-2.914 Cell 130, 906–917, September 7, 2007 ª2007 Elsevier Inc.Structural Rigidity of the LRR Modules
in the TLR4-VLR Hybrids
Since the structures of proteins adapt to the environments
provided by their sequences, our primary concern while
designing the TLR4-VLR hybrids was that fusion might
lead to unpredictable structural changes of the TLR4 or
VLR modules. We previously solved the crystal structures
of several VLR clones of Pacific hagfish (Kim et al., 2007).
To check for the presence of structural changes in the VLR
modules, we superimposed the structure of native
VLRB.61 on those of the VLR modules of the hybrid pro-
teins (Figure S6). The backbone atoms of the native and
hybrid proteins had practically identical structures, with
an average Ca rms difference of 0.30.4 A˚ after superim-
position. Since we did not know the structure of full-length
human TLR4, we could not directly compare the hybrid
structures to the structure of TLR4. Instead, we compared
the structures of the overlapping regions of the three TLR
hybrids. The entire length of the TLR4 fragment in the TV3
hybrid is included in the longer TV8 hybrids, and 145 res-
idues from amino acid 383 to 527 are common to the VT3
and the TV8 hybrids (Table S2). The overlapping regions
have practically identical backbone structures with aver-
age Ca rms differences of 0.39 A˚ and 0.28 A˚, respectively
(Figure S7). As a control, TLR3 structures determined in-
dependently by two research groups were superimposed,
and their average Ca rms difference was 1.1 A˚ (Bell et al.,
2005; Choe et al., 2005). Surprisingly, the structural ho-
mology is not restricted to the backbone atoms; even at
the fusion site the side chains have similar conformations,
apart from the long and flexible ones. The unexpected
structural rigidity of the LRR modules is surprising but un-
derstandable since the concave b strand region of LRR
proteins is an unusually rigid structural frame. From the
analysis described above, we were convinced that the
Hybrid LRR Technique did not cause substantial structural
changes.
Applications of the Hybrid LRR Technique
The Hybrid LRR Technique made two crucial contribu-
tions to our structural studies on the TLR4-MD-2 system.
(1) It was essential for crystallizing TLR4-MD-2 with bound
Eritoran. The mouse TLR4-MD-2 complex could not be
crystallized with LPS or LPS analogs, which made biolog-
ical interpretation of the structural results very difficult. To
solve this problem, we continued to generate new hybrids
until we found one that could be crystallized with bound li-
gands. The TV3 hybrid was the first to be crystallized with
MD-2 and Eritoran, and its structure was determined. (2)
The hybrid proteins were useful for structure determina-
tion. Although the mouse TLR4-MD-2 complex was crys-
tallized successfully, structure determination bymolecular
replacement using the TLR3 structure was not possible
due to substantial structural differences between TLR3
and TLR4. However, the short TV3 hybrid had consider-
able structural homology with the N-terminal portion of
TLR3, and its structure could be solved by molecular re-
placement using the reported TLR3 and VLR structures
as search probes. The refined structure of TV3 in turn
served as a good search probe for longer TLR4 fragments.
Furthermore, crystals of the smaller hybrid proteins
tended to diffract X-rays to high resolution, which greatly
simplified structure determination.
The Hybrid LRR Technique may have broader applica-
tions. It can be used to reduce the size of proteins to the
minimum required for function. It can also be applied to
generate multifunctional LRR proteins. For example, it
may be possible to design hybrid proteins with both
TLR4 and TLR2 activities. Such artificial proteins may
have beneficial properties as therapeutic reagents. Fusion
strategies similar to the Hybrid LRR Techniquemay be ap-
plicable to other repeat families such as the ankyrin or
WD40 repeat proteins.
In conclusion, we report the first crystal structures of
human and mouse TLR4-MD-2 complexes. Eritoran, an
antagonistic homolog of LPS, binds to a large internal
pocket in MD-2. Based on mutagenesis experiments on
MD-2 and TLR4, we propose a model of TLR4-MD-2
dimerization induced by LPS. The Hybrid LRR Technique
was needed for crystallographic study of TLR4-MD-2 and
may have broader applications in biological studies of
LRR family proteins and their medical uses.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification
The human TLR4-VLR hybrids (Table S2) were cloned into the BamHI
andNotI sites of pAcGP67 vector (BDBiosciences) by overlap PCR us-
ing the primers listed in Table S3. The Fc domain of human IgG1 and
a thrombin cleavage site was cloned between the NotI and the BglII
sites of pAcGP67. The resulting Fc-tagged hybrids were expressed
in Hi5 insect cells (Invitrogen) and purified by protein A SepharoseC(GE Healthcare) affinity chromatography. After cleavage by thrombin
to remove the Fc tag, the hybrid proteins were further purified by ion
exchange and gel filtration chromatography (Table S4). The wild-
type and mutant MD-2s fused to a protein A tag were coexpressed
with TLR4 or TLR4-VLR hybrids in Hi5 cells and purified by IgGSephar-
ose (GE Healthcare) affinity chromatography. The protein A tag was
removed by thrombin digestion and the TLR4-MD-2 complexes were
further purified by ion exchange and gel filtration chromatography
(Table S4).
Binding of LPS or Eritoran to the TLR4-MD-2 Complexes
E. coli LPSRa (Sigma, L9641) or Eritoranwere sonicated for 10min and
incubated with the TLR4-MD-2 complexes at 37C for 3 hr. Eritoran
was a generous gift from Eisai, Inc. The molar ratio of LPS or Eritoran
to the protein was kept at 10:1. The TV3-MD-2-Eritoran complex used
for crystallization was purified by Superdex-200 gel filtration chroma-
tography (GE Healthcare) to remove unbound Eritoran. Native PAGE
experiments were repeated using ultrapure LPS from List Biological
Lab. The LPS-bound protein bands were similarly upward shifted but
inmultiple bands due to heterogeneity of LPS (data not shown). Ramu-
tant form of LPS does not contain O-antigen sugar groups and has
lower heterogeneity. Addition of CD14 and LBP to the reaction mixture
sped up the reaction but did not change in yield and aggregation state
of the final products.
Crystallization and Data Collection
Crystals were grown for one week using the hanging-drop vapor diffu-
sion method by mixing 1 ml of protein solution and 1 ml of crystallization
buffer. The optimized crystallization conditions are summarized
in Table S4. For data collection, the crystals were flash-frozen
at 170C in freezing buffers (Table S4). Diffraction data were
collected at the 4A beam line of Pohang Accelerator Laboratory, the
BL41XU beam line of SPring-8, or the ID14-2 beam line of ESRF.
The HKL2000 package (Otwinowski and Minor, 1997) and the
MOSFLM/SCALA (Winn, 2003) programs were used to index, inte-
grate, and scale the diffraction data.
Structure Determination and Refinement
Initial phases were calculated bymolecular replacement using the pro-
gram PHASER (McCoy et al., 2005). The search probes used for the
calculation are summarized in Table S5. Atomic models were built by
iterative modeling and refinement using the program O and CNS
(Brunger et al., 1998; Jones et al., 1991). Atomic model of Eritoran
was built into a strong and continuous electron density that was found
in the MD-2 pocket (Figure S8). The final models were further refined
using the program REFMAC (Murshudov et al., 1997) with the TLS pro-
gram parameters generated by the TLSMD server (Painter and Merritt,
2006). No nonglycine residues are found in the disallowed regions of
the Ramachandran plots.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures,
eight figures, five tables, and references and can be foundwith this arti-
cle online at http://www.cell.com/cgi/content/full/130/5/906/DC1/.
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